Bull case
Biomea Fusion is viewed positively because its lead asset icovamenib has shown a differentiated, disease-modifying profile: in COVALENT-111, a 12-week course produced a 1.5% placebo-adjusted A1c reduction in insulin-deficient diabetes and a 1% reduction in GLP-failure patients, with C-peptide gains sustained through 52 weeks and roughly 25% probability of success cited ahead of 4Q26 readouts. The pipeline also broadens the thesis, as BMF-650 delivered early Phase 1 weight loss of 1.5% to 3.2% at day 29 versus 0.1% on placebo, with approximately 79,000 hour-nanograms per milliliter exposure and a peak-to-trough ratio near 1.7 supporting once-daily dosing and clinically relevant exposure. Importantly, both programs address large unmet needs in diabetes and obesity while showing encouraging tolerability and a potential strategic-partnering path, which supports meaningful upside from a small-cap, cash-trading valuation base.